Emyria (ASX:EMD) had positioned itself at the centre of a rapidly evolving global mental health landscape, launching a new service platform designed to support international drug sponsors as demand accelerates for next-generation therapies.

Click the link below to read the full article.

https://biotechdispatch.com.au/news/emyria-bets-on-global-demand-for-next-generation-mental-health-treatments